These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33975179)

  • 21. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
    Richard S; Jagannath S
    BioDrugs; 2022 Jan; 36(1):13-25. PubMed ID: 35113384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
    Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
    Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
    Totiger TM; Chaudhry S; Musi E; Afaghani J; Montoya S; Owusu-Ansah F; Lee S; Schwartz G; Klimek V; Taylor J
    J Cell Mol Med; 2023 Feb; 27(4):587-590. PubMed ID: 36722323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selinexor: Targeting a novel pathway in multiple myeloma.
    Mo CC; Yee AJ; Midha S; Hartley-Brown MA; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
    EJHaem; 2023 Aug; 4(3):792-810. PubMed ID: 37601856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors.
    Coutinho DF; Mundi PS; Marks LJ; Burke C; Ortiz MV; Diolaiti D; Bird L; Vallance KL; Ibáñez G; You D; Long M; Rosales N; Grunn A; Ndengu A; Siddiquee A; Gaviria ES; Rainey AR; Fazlollahi L; Hosoi H; Califano A; Kung AL; Dela Cruz FS
    Med; 2022 Nov; 3(11):774-791.e7. PubMed ID: 36195086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selinexor targeting XPO1 promotes PEG3 nuclear accumulation and suppresses cholangiocarcinoma progression.
    Xiang D; Wang M; Wu H; Chen X; Chen T; Yu D; Xiong L; Xu H; Luo M; Zhang S; Wu L; Yan J
    Cancer Chemother Pharmacol; 2024 Aug; ():. PubMed ID: 39103668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.
    Baek HB; Lombard AP; Libertini SJ; Fernandez-Rubio A; Vinall R; Gandour-Edwards R; Nakagawa R; Vidallo K; Nishida K; Siddiqui S; Wettersten H; Landesman Y; Weiss RH; Ghosh PM; Mudryj M
    Oncotarget; 2018 Oct; 9(77):34567-34581. PubMed ID: 30349650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma.
    Wang Y; Chen J; Gao Y; Chai KXY; Hong JH; Wang P; Chen J; Yu Z; Liu L; Huang C; Taib NAM; Lim KMH; Guan P; Chan JY; Huang D; Teh BT; Li W; Lim ST; Yu Q; Ong CK; Huang H; Tan J
    Cancer Lett; 2024 Aug; 597():217080. PubMed ID: 38908542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
    He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
    Nair JS; Musi E; Schwartz GK
    Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
    [No Abstract]   [Full Text] [Related]  

  • 32. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
    Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
    Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
    Onco Targets Ther; 2020; 13():6405-6416. PubMed ID: 32669858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
    Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
    Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.
    Li S; Fu J; Walker CJ; Yang J; Bhutani D; Chakraborty R; Mamillapalli N; Mapara MY; Landesman Y; Lentzsch S
    Blood Adv; 2023 Jun; 7(12):2926-2937. PubMed ID: 36827679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
    Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
    Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.
    Mittal S; Kadamberi IP; Chang H; Wang F; Kumar S; Tsaih SW; Walker CJ; Chaluvally-Raghavan P; Charlson J; Landesman Y; Pradeep S
    Exp Hematol Oncol; 2023 Sep; 12(1):78. PubMed ID: 37715291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.
    Burke RT; Marcus JM; Orth JD
    Oncotarget; 2017 Jun; 8(24):39460-39475. PubMed ID: 28467801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts.
    Rosen JC; Weiss J; Pham NA; Li Q; Martins-Filho SN; Wang Y; Tsao MS; Moghal N
    Transl Oncol; 2021 Oct; 14(10):101179. PubMed ID: 34284202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer.
    Rahman MM; van Oosterom F; Enow JA; Hossain M; Gutierrez-Jensen AD; Cashen M; Everts A; Lowe K; Kilbourne J; Daggett-Vondras J; Karr TL; McFadden G
    Cancer Res Commun; 2023 Jun; 3(6):952-968. PubMed ID: 37377603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.